Perrigo Receives FDA Approval for Calcium Acetate Capsules

Perrigo Company

today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for calcium acetate capsules, the generic equivalent of Phoslo(R) Gelcaps. Perrigo was previously in patent litigation over this product with the brand and the litigation settled in late 2011. The terms of the settlement are confidential. Gelcaps annual brand and equivalent generics sales were approximately $95 million, as measured by Wolters Kluwer Health. Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. This is another demonstration of our strategy to provide more affordable, high quality healthcare products to patients." Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx)